Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants

被引:205
作者
Hofmann, Marco H. [1 ]
Gerlach, Daniel [1 ]
Misale, Sandra [2 ]
Petronczki, Mark [1 ]
Kraut, Norbert [1 ]
机构
[1] Boehringer Ingelheim RCV GmbH & Co KG, Discovery Res, Vienna, Austria
[2] Mem Sloan Kettering Canc Ctr, Mol Pharmacol Program, 1275 York Ave, New York, NY 10021 USA
关键词
COLORECTAL-CANCER CRC; MEK INHIBITOR; ADAGRASIB MRTX849; SOLID TUMORS; GENOMIC ALTERATIONS; CELL-PROLIFERATION; KRYSTAL-1; ACTIVITY; AMG; 510; RAS; KRAS(G12C);
D O I
10.1158/2159-8290.CD-21-1331
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
KRAS is the most frequently mutated oncogene, harboring mutations in approximately one in seven cancers. Allele-specific KRAS(G12C) inhibitors are currently changing the treatment paradigm for patients with KRAS(G12C)-mutated non-small cell lung cancer and colorectal cancer. The success of addressing a previously elusive KRAS allele has fueled drug discovery efforts for all KRAS mutants. Pan-KRAS drugs have the potential to address broad patient populations, including KRAS(G12D)-, KRAS(G12V)-, KRAS(G13D)-, KRAS(G12R)-, and KRAS(G12A)-mutant or KRAS wild-typeamplified cancers, as well as cancers with acquired resistance to KRAS(G12C) inhibitors. Here, we review actively pursued allele-specific and pan-KRAS inhibition strategies and their potential utility. Significance: Mutant-selective KRAS(G12C) inhibitors target a fraction (approximately 13.6%) of all KRAS-driven cancers. A broad arsenal of KRAS drugs is needed to comprehensively conquer KRASdriven cancers. Conceptually, we foresee two future classes of KRAS medicines: mutant-selective KRAS drugs targeting individual variant alleles and pan-KRAS therapeutics targeting a broad range of KRAS alterations.
引用
收藏
页码:924 / 937
页数:14
相关论文
共 97 条
[1]   Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C-Mutant Non-Small Cell Lung Cancer [J].
Adachi, Yuta ;
Ito, Kentaro ;
Hayashi, Yuko ;
Kimura, Ryo ;
Tan, Tuan Zea ;
Yamaguchi, Rui ;
Ebi, Hiromichi .
CLINICAL CANCER RESEARCH, 2020, 26 (22) :5962-5973
[2]   Clinicopathological characteristics and treatment patterns observed in real-world care in patients with advanced non-small cell lung cancer (NSCLC) and KRAS G12C mutations in the Flatiron Health (FH)-Foundation Medicine (FMI) Clinico-Genomic Database (CGDB) [J].
Aggarwal, S. ;
Whipple, S. ;
Hsu, H. ;
Tu, H. ;
Carrigan, G. ;
Wang, X. ;
Ngarmchamnanrith, G. ;
Chia, V. .
ANNALS OF ONCOLOGY, 2020, 31 :S860-S860
[3]   EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer [J].
Amodio, Vito ;
Yaeger, Rona ;
Arcella, Pamela ;
Cancelliere, Carlotta ;
Lamba, Simona ;
Lorenzato, Annalisa ;
Arena, Sabrina ;
Montone, Monica ;
Mussolin, Benedetta ;
Bian, Yu ;
Whaley, Adele ;
Pinnelli, Marika ;
Murciano-Goroff, Yonina R. ;
Vakiani, Efsevia ;
Valeri, Nicola ;
Liao, Wei-Li ;
Bhalkikar, Anuja ;
Thyparambil, Sheeno ;
Zhao, Hui-Yong ;
de Stanchina, Elisa ;
Marsoni, Silvia ;
Siena, Salvatore ;
Bertotti, Andrea ;
Trusolino, Livio ;
Li, Bob T. ;
Rosen, Neal ;
Di Nicolantonio, Federica ;
Bardelli, Alberto ;
Misale, Sandra .
CANCER DISCOVERY, 2020, 10 (08) :1129-1139
[4]   AACR Project GENIE: Powering Precision Medicine through an International Consortium [J].
Andre, Fabrice ;
Arnedos, Monica ;
Baras, Alexander S. ;
Baselga, Jose ;
Bedard, Philippe L. ;
Berger, Michael F. ;
Bierkens, Mariska ;
Calvo, Fabien ;
Cerami, Ethan ;
Chakravarty, Debyani ;
Dang, Kristen K. ;
Davidson, Nancy E. ;
Del Vecchio, Fitz Catherine ;
Dogan, Semih ;
DuBois, Raymond N. ;
Ducar, Matthew D. ;
Futreal, P. Andrew ;
Gao Jianjiong ;
Garcia, Francisco ;
Gardos, Stu ;
Gocke, Christopher D. ;
Gross, Benjamin E. ;
Guinney, Justin ;
Heins, Zachary J. ;
Hintzen, Stephanie ;
Horlings, Hugo ;
Hudecek, Jan ;
Hyman, David M. ;
Kamel-Reid, Suzanne ;
Kandoth, Cyriac ;
Kinyua, Walter ;
Kumari, Priti ;
Kundra, Ritika ;
Ladanyi, Marc ;
Lefebvre, Celine ;
LeNoue-Newton, Michele L. ;
Lepisto, Eva M. ;
Levy, Mia A. ;
Lindeman, Neal, I ;
Lindsay, James ;
Liu, David ;
Lu Zhibin ;
MacConaill, Laura E. ;
Ian, Maurer ;
Maxwell, David S. ;
Meijer, Gerrit A. ;
Meric-Bernstam, Funda ;
Micheel, Christine M. ;
Miller, Clinton ;
Mills, Gordon .
CANCER DISCOVERY, 2017, 7 (08) :818-831
[5]   Acquired Resistance to KRASG12C Inhibition in Cancer [J].
Awad, M. M. ;
Liu, S. ;
Rybkin, I. I. ;
Arbour, K. C. ;
Dilly, J. ;
Zhu, V. W. ;
Johnson, M. L. ;
Heist, R. S. ;
Patil, T. ;
Riely, G. J. ;
Jacobson, J. O. ;
Yang, X. ;
Persky, N. S. ;
Root, D. E. ;
Lowder, K. E. ;
Feng, H. ;
Zhang, S. S. ;
Haigis, K. M. ;
Hung, Y. P. ;
Sholl, L. M. ;
Wolpin, B. M. ;
Wiese, J. ;
Christiansen, J. ;
Lee, J. ;
Schrock, A. B. ;
Lim, L. P. ;
Garg, K. ;
Li, M. ;
Engstrom, L. D. ;
Waters, L. ;
Lawson, J. D. ;
Olson, P. ;
Lito, P. ;
Ou, S. -H. I. ;
Christensen, J. G. ;
Janne, P. A. ;
Aguirre, A. J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (25) :2382-2393
[6]  
Bazhenova L, ANN ONCOL, V32, pS598, DOI [10.1016/annonc/annonc699, DOI 10.1016/ANNONC/ANNONC699]
[7]  
Bendell J, 2020, EUR J CANCER, V138, pS8
[8]   Equivalent effect of DNA damage-induced apoptotic cell death or long-term cell cycle arrest on colon carcinoma cell proliferation and tumour growth [J].
Bhonde, MR ;
Hanski, ML ;
Notter, M ;
Gillissen, BF ;
Daniel, PT ;
Zeitz, M ;
Hanski, C .
ONCOGENE, 2006, 25 (02) :165-175
[9]   Targeted Degradation of Oncogenic KRASG12C by VHL-Recruiting PROTACs [J].
Bond, Michael J. ;
Chu, Ling ;
Nalawansha, Dhanusha A. ;
Li, Ke ;
Crews, Craig M. .
ACS CENTRAL SCIENCE, 2020, 6 (08) :1367-1375
[10]   Initial results from a dose finding study of TNO155, a SHP2 inhibitor, in adults with advanced solid tumors. [J].
Brana, Irene ;
Shapiro, Geoffrey ;
Johnson, Melissa Lynne ;
Yu, Helena Alexandra ;
Robbrecht, Debbie ;
Tan, Daniel Shao-Weng ;
Siu, Lillian L. ;
Minami, Hironobu ;
Steeghs, Neeltje ;
Hengelage, Thomas ;
Tan, Eugene ;
Biette, Kelly ;
Xu, Kun ;
Moody, Susan Elizabeth ;
Jove, Maria .
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)